Dendreon’s Seal Beach plant: advertising campaign aimed at boosting demand for company’s flagship product A top executive of Seattle-based biotech Dendreon Corp., which has a manufacturing plant in ...

(Reuters) - Dendreon Corp filed for Chapter 11 bankruptcy protection after sales of the world's first cancer vaccine fell short of expectations and left the company deep in debt. More than two-thirds ...

The impact of slow sales of Dendreon‘s (NASDAQ:DNDN) prostate cancer treatment Provenge is reaching pharma giant GlaxoSmithKline (NYSE:GSK). Seattle biotech company Dendreon is terminating a supply ...

Tough times continue for Dendreon Corp., the Seattle biotech company with a plant in Seal Beach, where the company just cut 70 jobs, according to a filing with the state Employment Development ...

NEW YORK, April 14 (Reuters) - An experimental medicine from Dendreon Corp improved survival in men with advanced forms of prostate cancer, the company said on Tuesday, bolstering chances of it ...

I’ve been working on projects and taking days off here and there, so the blog has suffered, and I’ve missed out on some good biotech tidbits in the past couple of weeks. In the region’s biotech ...

) is down hugely this morning on last night's earnings miss and guidance rescission. The NASDAQ Biotech Index (^NBI) and associated ETF ( ) are down also. This is not a good day for the biotech sector ...

after the company reported its second quarter earnings results. It didn't go so well...the stock is down 62% in late trading! No one wants to see this (except the shorts, who are probably taking a ...

Shares of biotech Dendreon (NASDAQ: DNDN) swooned more than two-thirds on Aug. 4 — hit by uncertainty surrounding its prostate cancer drug sales. Shares of biotech Dendreon (NASDAQ: DNDN) swooned more ...

It’s been more than a decade since Dendreon’s prostate cancer immunotherapy, Provenge, won FDA approval. Now, after a lackluster launch, a bankruptcy and multiple ownership changes, the biopharma is ...

SEATTLE-- (BUSINESS WIRE)--July 30, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced a strategic restructuring plan designed to accelerate the Company’s path to profitability and future growth ...

Dendreon Corp. expanded its drug development and licensing collaboration with the pharmaceutical division of Kirin Brewery Co. Ltd. Dendreon, of Seattle, will provide Tokyo-based Kirin with extensive ...